Vaccine Adjuvant Market is estimated to be USD 6.4 Billion by 2034; Rising Prevalence of Infectious Diseases to Fuel the Market Growth

An adjuvant is a material or a substance used in some vaccines that helps vaccine to create a stronger immune response in people that receives the vaccines. The growing prevalence of lethal diseases like cervical cancer, Human Papillomavirus (HPV), HIV and tuberculosis that has led to an increase in demand for adjuvants. The adjuvants basically play a crucial role in enhancing the efficacy of vaccines that prevent the infectious diseases. The use of recombinant and synthetic vaccines has also led to increase in the demand of Vaccine Adjuvant Market. 

Another factor that helps the rising demand of the old age population among the world is an increase in demand or need of vaccinations that are effective and protect elderly people against variety of diseases. As there is an advancement in innovative vaccines antigens that often exhibit inadequate immunogenicity on their own, it has expected to fuel the growth of demand of vaccine adjuvants market over the coming years. Vaccine Adjuvant Market Size was valued at USD 2.2 Billion in 2024 and is expected to reach USD 6.4 Billion by 2034, growing at a CAGR of 13.0%

The report “Vaccine Adjuvant Market Size, Share, By Product Type (Particulate Adjuvants, Emulsion Adjuvants, Pathogen Adjuvants, Combination Adjuvants, and Other Adjuvants), By Route of Administration (Oral, Intranasal, Intramuscular, Subcutaneous, Intradermal, and Others), By Disease Type (Cancer, Infectious Disease, and Others), By Application (Research, Commercial, and Others), and By Region - Trends, Analysis and Forecast till 2034”

 Key Highlights:

• In May 2022, China’s National Medical Products Administration (NMPA) granted an approval for GlaxoSmithKline’s (GSK) Cervarix. This is a two-dose vaccine schedule. Used to prevent cervical cancer in girls between the age group of 14 years.   Cervarix is basically a recombinant and non-infectious vaccine.
• In July 2021, Dynavax Technologies Corp. and Biological E. Limited (BE) executed a commercial supply agreement of Dynavax’s CpG 1018TM called as CORBEVAX. It is an advanced adjuvant that is used in BE’s subunit COVID-19 vaccine candidate.
• In June 2021, Thermo Fisher Scientific entered an agreement with Moderna Inc., it is a biotechnology industry which involved in messenger RNA (mRNA) therapeutics and vaccines. The agreement basically provides and supply packaging for Moderna’s COVID-19 vaccine.

Analyst View:

The sudden increase of infectious disease like influenza, tuberculosis, malaria, and HIV, etc. has driven the growth of the Vaccine Adjuvant Market is growing prevalence of cancer diseases. Vaccine advancement is expected to boost the demand for Vaccine Adjuvant Market growth in future. This leads to the market competition which is way more intensifying, and big international industries and start-ups are struggling to establish position in the Vaccine Adjuvant market.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Vaccine Adjuvant Market Size, Share, By Product Type (Particulate Adjuvants, Emulsion Adjuvants, Pathogen Adjuvants, Combination Adjuvants, and Other Adjuvants), By Route of Administration (Oral, Intranasal, Intramuscular, Subcutaneous, Intradermal, and Others), By Disease Type (Cancer, Infectious Disease, and Others), By Application (Research, Commercial, and Others), and By Region - Trends, Analysis and Forecast till 2034”

Key Market Insights from the report:

Vaccine Adjuvant Market Size was valued at USD 2.2 Billion in 2024 and is expected to reach USD 6.4 Billion by 2034, growing at a CAGR of 13.0%. The Vaccine Adjuvant Market is segmented based on Product Type, Route of Administration, Disease Type, Application and Region.

• Based on Product Type, Vaccine Adjuvant Market is segmented into emulsion adjuvants, particulate adjuvants, pathogen adjuvants, combination adjuvants and other adjuvants.
• Based on route of administration, Vaccine Adjuvant Market is segmented into oral, intranasal, Intramuscular, intradermal, others.
• Based on route disease type, Vaccine Adjuvant Market is segmented into cancer, infectious disease and others.
• By Region, the Vaccine Adjuvant Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Competitive Landscape & their strategies of Vaccine Adjuvant Market:

The prominent players operating in the Vaccine Adjuvant Market includes, SEPPIC Inc., Novavax, Inc., Hayashibara Co., Ltd., SPI Pharma Inc, Invivogen, Avanti Polar Lipids, Inc., MPV Technologies, OZ Biosciences, Agenus, Inc., Brenntag Biosector, Spectrum Pharmaceuticals. Inc., Sigma Aldrich, Adjuatis, Vaxliant, Adjuvance Technologies, Inc., GlaxoSmithKline plc., Puma Biotechnology, Tj Kaiwei, Zhouyue, Aphios, and CSL Limited.

To know more

Contact Us:

Sales

Prophecy Market Insights

 U.S.  1 860 531 2574

RoW: 917775049802

Email- [email protected]

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com